SAKK 01/18 Reduced-intensity radio-chemotherapy in patients with stage IIA/B seminoma (testicular cancer). A multicenter, open-label phase II study with two patient groups.

The study is investigating whether and how the treatment of men with seminoma (testicular cancer) can be improved. In the study, patients are treated with a combination of chemotherapy and radiotherapy with reduced intensity. We want to find out whether this form of attenuated therapy is effective compared to standard therapy, whether possible side effects can be avoided and how this affects the patients' quality of life. This study is being conducted in Switzerland and Germany. A total of around 135 patients are taking part. The chemotherapy drugs used in the study are carboplatin (stage IIA) and cisplatin / etoposide (stage IIB and IIA), which are commonly used in the treatment of testicular cancer in Switzerland. The study therapy lasts around six weeks. Each participant is then followed up at regular intervals for 20 years.

(BASEC)